3,6,2′,4′-tetrahydroxyflavone

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 3,6,2′,4′-tetrahydroxyflavone
• 英文别名: 3,6,2′,4'-tetrahydroxyflavone；3,6,2',4'-tetrahydroxyflavone；2-(2,4-dihydroxy-phenyl)-3,6-dihydroxy-chromen-4-one；2-(2,4-Dihydroxy-phenyl)-3,6-dihydroxy-chromen-4-on；2-(2,4-dihydroxyphenyl)-3,6-dihydroxychromen-4-one
• 化学式: C₁₅H₁₀O₆
• 分子量: 286.241
• InChiKey: DNISTMYBAOCXPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3,6,2′,4′-tetrahydroxyflavone 在 三甲基铵三氧化硫共聚物 、 三乙胺 作用下， 以 乙腈 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  Discovery of novel sulfonated small molecules that inhibit vascular tube formation

  摘要：

  Tumor-associated angiogenesis is a complex process that involves the interplay among several molecular players such as cell-surface heparan sulfate proteoglycans, vascular endothelial growth factors and their cognate receptors. PI-88, a highly sulfonated oligosaccharide, has been shown to have potent anti-angiogenic activity and is currently in clinical trials. However, one of the major drawbacks of large oligosaccharides such as PI-88 is that their synthesis often requires numerous complex synthetic steps. In this study, several novel polysulfonated small molecule carbohydrate mimetics, which can easily be synthesized in fewer steps, are identified as promising inhibitors of angiogenesis in an in vitro tube formation assay. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.014
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 氢碘酸 作用下， 生成 3,6,2′,4′-tetrahydroxyflavone
  参考文献：
  名称：

  Bonifazi; v. Kostanecki; Tambor, Chemische Berichte, 1906, vol. 39, p. 89

  摘要：

  DOI：

文献信息

• [EN] COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERS<br/>[FR] COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：NUSIRT SCIENCES INC

  公开号：WO2018058109A1

  公开（公告）日：2018-03-29

  Methods and compounds useful for reducing, treating, preventing, or sustaining the reduction of a metabolic disease or disorder are provided herein. Also provided herein are compositions and kits for practicing any of the methods described herein.

  本文提供了用于减少、治疗、预防或维持代谢性疾病或紊乱的方法和化合物。本文还提供了用于实施本文中描述的任何方法的组合物和工具包。
• Compositions for treating or preventing obesity and insulin resistance disorders
  申请人：Sinclair A. David

  公开号：US20060111435A1

  公开（公告）日：2006-05-25

  Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.

  本文提供了一种调节sirtuin活性或水平的方法和组成物，从而治疗或预防主体的肥胖症或胰岛素抵抗障碍，例如糖尿病。示例方法包括使用sirtuin激活化合物或抑制化合物接触细胞，以此分别增加或减少脂肪积累。
• Methods and compositions for treating flushing and drug induced weight gain
  申请人：Sinclair David

  公开号：US20060276416A1

  公开（公告）日：2006-12-07

  Provided herein are methods and compositions for treating and/or preventing flushing and/or weight gain. Methods may comprise modulating the activity or level of a sirtuin, such as SIRT1 or Sir2. Exemplary embodiments include methods and compositions for counteracting drug-induced weight gain and/or drug-induced flushing by administering a sirtuin-activating compound.

  本文提供了用于治疗和/或预防面部潮红和/或体重增加的方法和组合物。方法可以包括调节sirtuin的活性或水平，例如SIRT1或Sir2。示例实施方式包括通过给予sirtuin激活化合物来抵消药物引起的体重增加和/或药物引起的面部潮红的方法和组合物。
• Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
  申请人：Milburn Michael

  公开号：US20060276393A1

  公开（公告）日：2006-12-07

  Provided herein are methods and compositions for treating or preventing neurodegenerative disorders or blood coagulation disorders. Methods may comprise modulating the activity or level of a sirtuin, such as SIRT1 or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin; or an inhibitory compound, such as nicotinamide.

  本文提供了治疗或预防神经退行性疾病或血液凝固疾病的方法和组合物。方法可以包括调节sirtuin的活性或水平，例如SIRT1或Sir2。示例方法包括使用sirtuin激活化合物（例如黄酮，苯乙烯，黄烷酮，异黄酮，儿茶素，查尔酮，单宁或花青素）或抑制化合物（例如烟酰胺）与细胞接触。
• Treatment of eye disorders with sirtuin modulators
  申请人：Milburn Michael

  公开号：US20060292099A1

  公开（公告）日：2006-12-28

  Sirtuin modulators, particularly sirtuin activators, are useful in treating vision impairment. In general, the sirtuin modulators inhibit the progression of vision impairment resulting from various eye disorders. The invention also includes pharmaceutically acceptable formulations of sirtuin modulators, particular ophthalmically acceptable formulations.

  西图因调节剂，特别是西图因激活剂，对于治疗视力受损很有用。一般来说，西图因调节剂抑制各种眼部疾病导致的视力受损的进展。该发明还包括西图因调节剂的药学可接受配方，特别是眼科可接受配方。